Associations - SF3B1 mutation

SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks (NewC2)	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks (NewC2)	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	venetoclax Resistant: C3 – Early Trials EHA 2022 - 2 weeks (NewC3)	venetoclax Resistant: C3 – Early Trials EHA 2022 - 2 weeks - (New D)
SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	venetoclax Resistant: C3 – Early Trials EHA 2022 - 2 weeks (NewC3)	venetoclax Resistant: C3 – Early Trials EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline	luspatercept-aamt Sensitive: A2 - Guideline
SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	ofatumumab Resistant: B - Late Trials	ofatumumab Resistant: B - Late Trials
SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	chlorambucil Resistant: B - Late Trials	chlorambucil Resistant: B - Late Trials
SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials	obinutuzumab Resistant: B - Late Trials
SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials	cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	SF3B1 mutation SF3B1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV 075 Sensitive: C3 – Early Trials	venetoclax + ABBV 075 Sensitive: C3 – Early Trials
SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
SF3B1 mutation SF3B1 mutation	Chronic Myeloid Leukemia CML	SF3B1 mutation SF3B1 mutation	Chronic Myeloid Leukemia CML	VE-821 Sensitive: D – Preclinical	VE-821 Sensitive: D – Preclinical